Skip to main content

Table 2 Incidence (per 100 person-years) of outcomes among the ACEi and ARB users after propensity score weighting

From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

 

Incidence (95 % CI)

Hazard ratio (95 % CI)

ACEi (n = 6898)

ARB (n = 12,758)

ACEi vs. ARB

P value

MACE

 Any MACEa

9.33 (8.90−9.76)

9.62 (9.16−10.08)

1.03 (0.96−1.10)

0.4244

 Cogestive heart failure

1.48 (1.33−1.63)

1.51 (1.35−1.67)

1.06 (0.91−1.22)

0.4538

 Stroke

3.78 (3.53−4.03)

3.56 (3.31−3.82)

1.12 (1.02−1.24)

0.0230

 Malignant dysrhythmia

0.16 (0.12−0.21)

0.15 (0.10−0.20)

1.14 (0.73−1.77)

0.5571

 Cardiogenic shock

0.03 (0.01−0.06)

0.04 (0.02−0.07)

0.81 (0.31−2.07)

0.6547

 MI or PCI

1.77 (1.61−1.93)

2.19 (2.00−2.39)

0.89 (0.78−1.01)

0.0646

 CABG

0.18 (0.13−0.23)

0.22 (0.16−0.28)

0.89 (0.60−1.31)

0.5438

 Thrombolysis therapy

0.00 (0.00−0.02)

0.02 (0.01−0.05)

0.19 (0.02−1.66)

0.1339

 ESRD

0.44 (0.36−0.52)

0.63 (0.53−0.73)

0.69 (0.54−0.88)

0.0025

  1. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CI confidence interval, MACE major adverse cardiovascular disease, MI myocardial infarction, CHF cogestive heart failure, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery, ESRD end stage renal disease
  2. aMACE = CHF or stroke or malignant dysrhythmia or cardiogenic shock or MI or PCI or CABG or thrombolysis therapy